Rising Biosciences Announces Official Sales and Distribution of its RSB0238 Clinical Strength Peptide Complex on Amazon
Date : 05/01/2018 @ 1:10PM
Source : InvestorsHub NewsWire
Stock : Rising India Inc. (PC) (RSII)
Quote : 0.01504 -0.00046 (-2.97%) @ 1:58PM
Rising Biosciences Announces Official Sales and Distribution of its RSB0238 Clinical Strength Peptide Complex on Amazon
Print
Alert
Rising Biosciences Announces Official Sales and Distribution of its RSB0238 Clinical Strength Peptide Complex on Amazon
RSII's serum ranks among top best-sellers in its category
Sandusky, OH -- May 01, 2018 -- InvestorsHub NewsWire -- Rising India, Inc.'s Rising Biosciences (OTC:RSII) ("RSII" "the Company"
, a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry, is pleased to announce that Amazon is now officially stocking and fulfilling orders via Amazon distribution centers throughout the USA for the Company's revolutionary RSB0238 Clinical Strength Peptide Complex. (product link: https://www.amazon.com/dp/B07CJKTZ2M/ref=cm_s...Ab5X0TMAY)
Amazon Prime members receive free two day shipping on the serum, which debuted to 5-star reviews and ranked among the best-selling new releases in the facial serum category.
COO Arthur Hall commented: "This is the first of many RSII products that we'll be offering via Amazon distribution centers throughout the United States with all order fulfillment performed directly by Amazon. RSII has achieved a highly desirable relationship here, and one we intend to further cultivate. I hope that it is clear to all that this is a monumental achievement for RSII that I believe will propel RSII to the next level of growth. That being said, We are also working with a broker to establish a presence in nationally recognized brick and mortar stores throughout the country."
Rising Biosciences team is thrilled to announce that their next product moving into production is its RBS0346 Clinical Strength Stem Cell Cream.
Hall comments, "It's safe to say that the anti-aging skin care market is not slowing down anytime soon. The global skin care industry is estimated to reach $131 billion in 2019 and we intend to capture an impactful market share as we continue to innovate and deliver products with unparalleled effect."
"Rising Biosciences Inc. along with PAO Group Inc. helping reduce the grip of opiods on America through the responsible use of cannabis"
$RSII on Twitter for LIVE company updates! www.twitter.com/risingindiausa
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.
CONTACT INFO:
For Investor Inquiries:
IR@risingbiosciences.com
Date : 05/01/2018 @ 1:10PM
Source : InvestorsHub NewsWire
Stock : Rising India Inc. (PC) (RSII)
Quote : 0.01504 -0.00046 (-2.97%) @ 1:58PM
Rising Biosciences Announces Official Sales and Distribution of its RSB0238 Clinical Strength Peptide Complex on Amazon
Alert
Rising Biosciences Announces Official Sales and Distribution of its RSB0238 Clinical Strength Peptide Complex on Amazon
RSII's serum ranks among top best-sellers in its category
Sandusky, OH -- May 01, 2018 -- InvestorsHub NewsWire -- Rising India, Inc.'s Rising Biosciences (OTC:RSII) ("RSII" "the Company"
, a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry, is pleased to announce that Amazon is now officially stocking and fulfilling orders via Amazon distribution centers throughout the USA for the Company's revolutionary RSB0238 Clinical Strength Peptide Complex. (product link: https://www.amazon.com/dp/B07CJKTZ2M/ref=cm_s...Ab5X0TMAY) Amazon Prime members receive free two day shipping on the serum, which debuted to 5-star reviews and ranked among the best-selling new releases in the facial serum category.
COO Arthur Hall commented: "This is the first of many RSII products that we'll be offering via Amazon distribution centers throughout the United States with all order fulfillment performed directly by Amazon. RSII has achieved a highly desirable relationship here, and one we intend to further cultivate. I hope that it is clear to all that this is a monumental achievement for RSII that I believe will propel RSII to the next level of growth. That being said, We are also working with a broker to establish a presence in nationally recognized brick and mortar stores throughout the country."
Rising Biosciences team is thrilled to announce that their next product moving into production is its RBS0346 Clinical Strength Stem Cell Cream.
Hall comments, "It's safe to say that the anti-aging skin care market is not slowing down anytime soon. The global skin care industry is estimated to reach $131 billion in 2019 and we intend to capture an impactful market share as we continue to innovate and deliver products with unparalleled effect."
"Rising Biosciences Inc. along with PAO Group Inc. helping reduce the grip of opiods on America through the responsible use of cannabis"
$RSII on Twitter for LIVE company updates! www.twitter.com/risingindiausa
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.
CONTACT INFO:
For Investor Inquiries:
IR@risingbiosciences.com
1
